Tarsus Pharmaceuticals (NASDAQ:TARS) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Head-To-Head Contrast

Tarsus Pharmaceuticals (NASDAQ:TARS) and Citius Pharmaceuticals (NASDAQ:CTXR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for Tarsus Pharmaceuticals and Citius Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1	1	6	2	2.90
Citius Pharmaceuticals	1	1	3	0	2.40

Tarsus Pharmaceuticals presently has a consensus target price of $100.86, suggesting a potential upside of 33.25%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 764.15%. Given Citius Pharmaceuticals’ higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.

Volatility & Risk

Tarsus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Profitability

This table compares Tarsus Pharmaceuticals and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

Insider and Institutional Ownership

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and Citius Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36 million	7.36	-$66.42 million	($1.09)	-69.44
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($1.67)	-0.35

Citius Pharmaceuticals has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Tarsus Pharmaceuticals beats Citius Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.